Regeneron Pharmaceuticals, Inc.
REGN · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Regeneron Pharmaceuticals, Inc. at a glance
In FY2025, Regeneron Pharmaceuticals, Inc. reported revenue of USD 14,343 mn, EBITDA of USD 4,246 mn, EBITDA margin of 29.6%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 14,202 | 14,343 | |||
| EBITDA | 4,575 | 4,246 | |||
| EBITDA margin | 32.2% | 29.6% | |||
| Free cash flow | 3,665 | 4,081 | |||
| ROIC | 21.6% | 14.8% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas